A Phase II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Relapsed or Refractory Waldenstrom's Macroglobulinemia

被引：0
|
作者：
Ghobrial, Irene M.
Gertz, Morie A.
LaPlant, Betsy
Camoriano, John [3 ]
Hayman, Suzanne R.
Lacy, Martha Q.
Chuma, Stacey
Sheehy, Patricia [1 ]
Harris, Brianna
Leduc, Renee
Rourke, Meghan
Ansell, Stephen M. [2 ]
DeAngelo, Daniel J. [1 ]
Dispenzieri, Angela
Bergsagel, Leif [3 ]
Reeder, Craig B. [3 ]
Anderson, Kenneth C.
Richardson, Paul
Treon, Steven
Witzig, Thomas E. [2 ]
机构：
[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[2] Mayo Clin, Coll Med, Rochester, MN USA
[3] Mayo Clin, Scottsdale, AZ USA
来源：
BLOOD | 2009年 / 114卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：244 / 244
页数：1
相关论文
共 50 条
  • [41] Phase I study of the oral mammalian target of rapamycin inhibitor everolimus (RAD001) in Japanese patients with relapsed or refractory non-Hodgkin lymphoma
    Tobinai, Kensei
    Ogura, Michinori
    Maruyama, Dai
    Uchida, Toshiki
    Uike, Naokuni
    Choi, Ilseung
    Ishizawa, Kenichi
    Itoh, Kuniaki
    Ando, Kiyoshi
    Taniwaki, Masafumi
    Shimada, Naomi
    Kobayashi, Ken
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2010, 92 (04) : 563 - 570
  • [42] Role of the Novel mTOR Inhibitor RAD001 (Everolimus) in Anaplastic Thyroid Cancer
    Papewalis, C.
    Wuttke, M.
    Schinner, S.
    Willenberg, H. S.
    Baran, A. M.
    Scherbaum, W. A.
    Schott, M.
    HORMONE AND METABOLIC RESEARCH, 2009, 41 (10) : 752 - 756
  • [43] Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma
    Oudard, Stephane
    Medioni, Jacques
    Aylllon, Jorge
    Barrascourt, Eduardo
    Elaidi, Reza-Thierry
    Balcaceres, Jose
    Scotte, Florian
    EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (06) : 705 - 717
  • [44] Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia.
    Ghobrial, Irene M.
    Hong, Fangxin
    Padmanabhan, Swaminathan
    Badros, Ashraf Z.
    Rourke, Meghan
    Leduc, Renee
    Chuma, Stacey
    Kunsman, Janet
    Warren, Diane
    Harris, Brianna
    Sam, Amy
    Anderson, Kenneth C.
    Richardson, Paul
    Treon, Steven
    Weller, Edie
    Matous, Jeffrey
    BLOOD, 2009, 114 (22) : 1067 - 1067
  • [45] Phase II Trial of Weekly Bortezomib in Combination With Rituximab in Relapsed or Relapsed and Refractory Waldenstrom Macroglobulinemia
    Ghobrial, Irene M.
    Hong, Fangxin
    Padmanabhan, Swaminathan
    Badros, Ashraf
    Rourke, Meghan
    Leduc, Renee
    Chuma, Stacey
    Kunsman, Janet
    Warren, Diane
    Harris, Brianna
    Sam, Amy
    Anderson, Kenneth C.
    Richardson, Paul G.
    Treon, Steven P.
    Weller, Edie
    Matous, Jeffrey
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (08) : 1422 - 1428
  • [46] A phase I/II study of the oral mTOR inhibitor RAD001 in patients with advanced hematologic malignancies.
    Yee, KWL
    Wierda, W
    O'Brien, S
    Thomas, D
    Kurzrock, R
    Fayad, LE
    Hagemeister, FB
    Cortes, J
    Prestifilippo, K
    Szatrowski, TP
    Kantarjian, HM
    Giles, FJ
    BLOOD, 2004, 104 (11) : 287B - 287B
  • [47] A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma
    Renner, Christoph
    Zinzani, Pier Luigi
    Gressin, Remy
    Klingbiel, Dirk
    Dietrich, Pierre-Yves
    Hitz, Felicitas
    Bargetzi, Mario
    Mingrone, Walter
    Martinelli, Giovanni
    Trojan, Andreas
    Bouabdallah, Krimo
    Lohri, Andreas
    Gyan, Emmanuel
    Biaggi, Christine
    Cogliatti, Sergio
    Bertoni, Francesco
    Ghielmini, Michele
    Brauchli, Peter
    Ketterer, Nicolas
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (07): : 1085 - 1091
  • [48] PHASE II STUDY OF MTOR-INHIBITOR RAD001 AND ERLOTINIB FOR ADVANCED, GEMCITABINE-REFRACTORY PANCREATIC CANCER
    Javle, M.
    Reddy, S.
    Varadhachary, G.
    Kaseb, A.
    Fogelman, D.
    Wolff, R.
    Abbruzzese, J.
    PANCREAS, 2008, 37 (04) : 476 - 476
  • [49] Phase II study of MTOR-inhibitor RAD001 and erlotinib for advanced, gemcitabine-refractory pancreatic cancer
    Javle, M.
    Fogelman, D.
    Kaseb, A.
    Varadhachary, G.
    Wolff, R.
    Abbruzzese, J.
    EJC SUPPLEMENTS, 2008, 6 (12): : 104 - 104
  • [50] The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer:: Results of a phase I study with pharmacokinetics
    Awada, Ahmad
    Cardoso, Fatima
    Fontaine, Christel
    Dirix, Luc
    De Greve, Jacques
    Sotiriou, Christos
    Steinseifer, Jutta
    Wouters, Carine
    Tanaka, Chiaki
    Zoellner, Ulrike
    Tang, Pui
    Piccart, Martine
    EUROPEAN JOURNAL OF CANCER, 2008, 44 (01) : 84 - 91
12345